ApoE Genotyping Analysis in Patients with Suspected Non-haemorrhagic Amyloid Angiopathy

NCT06809062 | Not Yet Recruiting

• 1 other identifier: LOCAL/2024/DR-04
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Ischaemic microangiopathic features have recently been incorporated into the criteria for cerebral amyloid angiopathy (CAA). ApoE genotyping (presence of the E4 allele) is routinely used to help determine the aetiology of a haemorrhagic microangiopathy found on MRI. Chronic ischaemic disease in CAA is characterised by the presence of :

• multispot pattern on the FLAIR sequence
• severe periventricular FLAIR hypersignals with posterior predominance The main aim of this study was therefore to analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected CAA based on ischaemic MRI involvement with a typical radiological pattern.

Conditions

Amyloid Angiopathy

Keywords

Cerebral Amyloid Angiopathy

Outcome Measures

Primary Outcomes (1)

• ApoE genotypage

  To analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected AAC. Endpoint: presence of the E4 allele (Yes/No).

  baseline

Study Arms (1)

ischaemic microangiopathy

The study is aimed at patients with manifestations related to a vascular accident visible on MRI.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with ischaemic stroke (from causes other than CAA, as CAA is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on MRI that may suggest associated CAA.

You may qualify if:

• Patients with ischaemic stroke (from causes other than CAA, as CAA is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on MRI that may suggest associated CAA.
• Patients treated at Nîmes University Hospital

You may not qualify if:

• Patient refusing to participate

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

MeSH Terms

Conditions

Amyloid angiopathy; Cerebral Amyloid Angiopathy

Condition Hierarchy (Ancestors)

Cerebral Arterial Diseases; Intracranial Arterial Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Amyloidosis; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Anissa MEGZARI

  Centre Hospitalier Universitaire de Nīmes

  STUDY DIRECTOR

Central Study Contacts

Dimitri RENARD, MD

CONTACT

(+33) 04.66.68.32.61; dimitri.renard@chu-nimes.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 24, 2025
• First Posted: February 5, 2025
• Study Start: February 1, 2025
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: February 5, 2025

Record last verified: 2025-01